Meet the editors

Raymond Nims has more than 37 years of experience in the biomedical sciences. He currently provides consulting services as an employee of RMC Pharmaceutical Solutions. From 2006 to 2009, Dr. Nims served in Amgen's corporate quality control group, providing subject matter expertise in viral and mycoplasma testing of raw materials and products, and serving as business process owner for Amgen's global contract analytical testing

lab outsourcing program. From 1994 to 2006, he directed laboratories at BioReliance, performing viral safety, endotoxin, and cell-line identity studies for biologics cell-line characterization, raw material testing, and product lot release testing. From 1985 to 1994, he served as a chemist at the National Cancer Institute's Laboratory of Chemical Carcinogenesis. Dr. Nims obtained a Ph.D. in Chemistry (Chemical Toxicology) at The American University, Washington, DC, in 1993. He currently serves on the editorial board for *BioProcessing Journal* and has served on the ad hoc advisory boards for USP chapters 1237, 1050, and 1050.1. He is a generalist in the biomedical sciences, with a publication list spanning a wide range of topics in chemistry, carcinogenesis, biochemistry, pharmacology, toxicology, and virology.

Dr. M. Khalid Ijaz is currently a Senior Research Fellow and Director of Scientific Affairs at Global Research & Development for Lysol and Dettol, Reckitt Benckiser LLC (RB). He obtained his DVM and MSc (Honors) from the Faculty of Veterinary Science, University of Agriculture, Faisalabad, Pakistan, and his Ph.D. in Microbiology and Immunology (Environmental Virology) from the University of Ottawa, Canada. He did post-doctoral

work in immunobiology/vaccinology with Dr. Lorne A. Babiuk at the Vaccines and Infectious Disease Organization (VIDO), University of Saskatchewan, Canada. His research focuses over the years have included aerobiology studies on enteric and respiratory viruses (human coronavirus, rhinovirus, rotavirus, and polioviruses), and interruption of the chain of infection of human pathogens via the environment and hands through targeted use of surface and hand hygiene agents. More recently, Dr. Ijaz's research interests have included the efficacy of microbicidal actives for inactivating World Health Organization priority list viruses, including human coronaviruses (SARS-CoV, MERS-CoV, and SARS-CoV-2), the filovirus Ebola virus, the arenavirus Lassa virus, and the paramyxovirus Nipah virus.
